Function of histone deacetylase inhibitors in inflammation

Critical Reviews in Immunology

Volumn 31, Issue 3, 2011, Pages 233-263

  Grabiec, Aleksander M ^a   Tak, Paul P ^a   Reedquist, Kris A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acetylation; Chronic obstructive pulmonary disease; Hdac; Rheumatoid arthritis; Sirtuin; Systemic onset juvenile idiopathic arthritis

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CAMBINOL; DACINOSTAT; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; ROMIDEPSIN; SHORT CHAIN FATTY ACID; SIRTINOL; SIRTUIN; SK 7041; SK 7068; STAT PROTEIN; TETRAPEPTIDE; TRANSCRIPTION FACTOR; TRICHOSTATIN A; TUBACIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ADAPTIVE IMMUNITY; ADJUVANT ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; EPIGENETICS; GENE EXPRESSION REGULATION; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STROMA CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 79959301511     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v31.i3.40     Document Type: Article

References (178)

1. Pearce EL, Shen H. Making sense of inflammation, epige-netics, and memory CD8+ T-cell differentiation in the context of infection. Immunol Rev. 2006 Jun;211:197-202.
2. Villagra A, Sotomayor EM, Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene. 2010 Jan 14;29(2):157-73.
3. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009 Oct 29;114(18):3727-35.
4. Cuddapah S, Barski A, Zhao K. Epigenomics of T cell activation, differentiation, and memory. Curr Opin Immunol. 2010 Jun;22(3):341-7.
5. Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009 Dec;6(8):693-6.
6. Huber LC, Stanczyk J, Jungel A, Gay S. Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum. 2007 Nov;56(11):3523-31.
7. Zhao S, Long H, Lu Q. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin Rev Allergy Immunol. 2010 Aug;39(1):3-9.
8. Strietholt S, Maurer B, Peters MA, Pap T, Gay S. Epige-netic modifcations in rheumatoid arthritis. Arthritis Res Ther. 2008;10(5):219.
9. Grabiec AM, Tak PP, Reedquist KA. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of infammatory disease: should we keep our HATs on? Arthritis Res Ther. 2008;10(5):226.
10. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational defnition of epigenetics. Genes Dev. 2009 Apr 1;23(7):781-3.
11. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007 May 24;447(7143): 407-12.
12. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, Gregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005 Jun 10;23(17):3923-31.
13. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantu D, Gonza-lez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-Plasen-cia C, Cabrera G, Trejo-Becerril C, Angeles E, Duenas-Gonzalez A. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005;4(1):22.
14. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, Prakken BJ, Maslinski W, Eldering E, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress infammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol. 2010 Mar 1;184(5):2718-28.
15. Ellis DJ, Lawman ZK, Bonham K. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem Biophys Res Commun. 2008 Mar 14;367(3):656-62.
16. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004 Apr 16;338(1):17-31.
17. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005 Dec 19;363:15-23.
18. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40.
19. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacety-lases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008 Mar;9(3):206-18.
20. Parra M, Verdin E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr Opin Pharmacol. 2010 Aug;10(4):454-60.
21. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, La-zar MA, Voelter W, Verdin E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell. 2002 Jan;9(1):45-57.
22. Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Ned-dermann P, Sambucini S, Bottomley MJ, Lo SP, Carf A, Koch U, De FR, Steinkuhler C, Gallinari P. Unraveling the hidden catalytic activity of vertebrate class IIa his-tone deacetylases. Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17335-40.
23. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the 'magnifcent seven', function, metabolism and longevity. Ann Med. 2007;39(5):335-45.
24. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007 May 15;404(1):1-13.
25. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kur-land I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Es-pinosa JM, Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010 Jan 22;140(2):280-93.
26. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 Jan;10(1):32-42.
27. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN. Histone deacetylas-es 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007 Jul 15;21(14):1790-802.
28. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Mat-suzaki S, Humphries KM, Richardson JA, Bassel-Duby R, Olson EN. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest. 2008 Nov;118(11):3588-97.
29. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liver-specifc deletion of histone deacety-lase 3 disrupts metabolic transcriptional networks. EMBO J. 2008 Apr 9;27(7):1017-28.
30. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell. 2004 Nov 12;119(4):555-66.
31. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004 Oct;24(19):8467-76.
32. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Por-rett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, Hancock WW. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007 Nov;13(11):1299-307.
33. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006 Jul 28;126(2):321-34.
34. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG, Verdin E. HDAC7, a thymus-specifc class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity. 2003 May;18(5):687-98.
35. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin S, Matthias P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008 Mar;28(5):1688-701.
36. Serrador JM, Cabrero JR, Sancho D, Mittelbrunn M, Urzainqui A, Sanchez-Madrid F. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity. 2004 Apr;20(4):417-28.
37. Cabrero JR, Serrador JM, Barreiro O, Mittelbrunn M, Naranjo-Suarez S, Martin-Cofreces N, Vicente-Man-zanares M, Mazitschek R, Bradner JE, Avila J, Valen-zuela-Fernandez A, Sanchez-Madrid F. Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell. 2006 Aug;17(8):3435-45.
38. Sequeira J, Boily G, Bazinet S, Saliba S, He X, Jardine K, Kennedy C, Staines W, Rousseaux C, Mueller R, McBurney MW. Sirt1-null mice develop an autoimmune-like condition. Exp Cell Res. 2008 Oct 1;314(16):3069-74.
39. Zhang J, Lee SM, Shannon S, Gao B, Chen W, Chen A, Di-vekar R, McBurney MW, Braley-Mullen H, Zaghouani H, Fang D. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest. 2009 Oct;119(10):3048-58.
40. Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, Fessler MB, Purushotham A, Li X. Myeloid deletion of SIRT1 induces infammatory signaling in response to environmental stress. Mol Cell Biol. 2010 Oct;30(19):4712-21.
41. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetyla-tion. Science. 2001 Aug 31;293(5535):1653-7.
42. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kap-paB. EMBO J. 2002 Dec 2;21(23):6539-48.
43. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specifc binding to acetylated RelA. Mol Cell Biol. 2009 Mar;29(5):1375-87.
44. Kiernan R, Bres V, Ng RW, Coudart MP, El MS, Sar-det C, Jin D Y, Emiliani S, Benkirane M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem. 2003 Jan 24;278(4):2758-66.
45. Ashburner BP, Westerheide SD, Baldwin AS. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol. 2001 Oct;21(20):7065-77.
46. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-depen-dent transcription and cell survival by the SIRT1 deacety-lase. EMBO J. 2004 Jun 16;23(12):2369-80.
47. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Sub-eroylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem. 2006 Mar 3;281(9):5612-22.
48. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford). 2008 Apr;47(4):409-14.
49. Cao W, Bao C, Padalko E, Lowenstein CJ. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med. 2008 Jun 9;205(6):1491-503.
50. Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Eur J Pharmacol. 2009 Nov 25;623(1-3):22-9.
51. Yamaguchi K, Lantowski A, Dannenberg AJ, Subbarama-iah K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem. 2005 Sep 23;280(38):32569-77.
52. Weiss C, Schneider S, Wagner EF, Zhang X, Seto E, Bo-hmann D. JNK phosphorylation relieves HDAC3-depen-dent suppression of the transcriptional activity of c-Jun. EMBO J. 2003 Jul 15;22(14):3686-95.
53. Gao Z, Ye J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun. 2008 Nov 28;376(4):793-6.
54. Klampfer L, Huang J, Swaby LA, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem. 2004 Jul 16;279(29):30358-68.
55. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, Ram-ratnam B, Chin YE. Acetylation-dependent signal trans-duction for type I interferon receptor. Cell. 2007 Oct 5;131(1):93-105.
56. Kramer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Guhrs KH, Stauber RH, Bohmer FD, Heinzel T. A phos-phorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009 Jan 15;23(2):223-35.
57. Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specifc DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem. 2005 Mar 25;280(12):11528-34.
58. Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, Gatza E, Mascagni P, Dinarello CA, Reddy P. Cutting edge: Negative regulation of dendritic cells through acety-lation of the nonhistone protein STAT-3. J Immunol. 2009 May 15;182(10):5899-903.
59. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimeriza-tion regulated by reversible acetylation of a single lysine residue. Science. 2005 Jan 14;307(5707):269-73.
60. Sebastian C, Serra M, Yeramian A, Serrat N, Lloberas J, Celada A. Deacetylase activity is required for STAT5-de-pendent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J Immunol. 2008 May 1;180(9):5898-906.
61. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ort-mann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5.
62. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003 Mar 17;197(6):711-23.
63. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003 Dec;36(8):481-90.
64. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Bag-gen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Di-jkstra CD, Polman CH, Verweij CL. A subtype of multiple sclerosis defned by an activated immune defense program. Genes Immun. 2006 Sep;7(6):522-31.
65. Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL. Rheumatoid arthritis subtypes identifed by genomic profling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007 Aug;66(8):1008-14.
66. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Bio-chem Soc Trans. 2006 Nov;34(Pt 5):647-62.
67. van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 2007 Jun;8(6):440-50.
68. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004 Mar 26;303(5666):2011-5.
69. Peng SL. Foxo in the immune system. Oncogene. 2008 Apr 7;27(16):2337-44.
70. Lin L, Hron JD, Peng SL. Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity. 2004 Aug;21(2):203-13.
71. Ouyang W, Beckett O, Ma Q, Paik JH, DePinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol. 2010 Jul;11(7):618-27.
72. Jonsson H, Allen P, Peng SL. Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nat Med. 2005 Jun;11(6):666-71.
73. Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev. 2009 Mar;228(1):132-48.
74. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gri-bling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS. Specifc Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011 Jan;7(1):41-50.
75. Liu Z, Mai A, Sun J. Lysine acetylation regulates Bruton's tyrosine kinase in B cell activation. J Immunol. 2010 Jan 1;184(1):244-54.
76. Bartl S, Taplick J, Lagger G, Khier H, Kuchler K, Seis-er C. Identifcation of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol Cell Biol. 1997 Sep;17(9):5033-43.
77. Aung HT, Schroder K, Himes SR, Brion K, van ZW, Trieu A, Suzuki H, Hayashizaki Y, Hume DA, Sweet MJ, Rava-si T. LPS regulates proinfammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 2006 Jul;20(9):1315-27.
78. Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K, Kadota Y, Inagaki J, Hirohata S, Ninomiya Y, Makino H. Increased activity and expression of histone deacety-lase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R133.
79. Navarro MN, Goebel J, Feijoo-Carnero C, Morrice N, Cantrell DA. Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol. 2011 Apr;12(4):352-61.
80. Pfum MK, Tong JK, Lane WS, Schreiber SL. Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J Biol Chem. 2001 Dec 14;276(50):47733-41.
81. Osoata GO, Yamamura S, Ito M, Vuppusetty C, Adcock IM, Barnes PJ, Ito K. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Bio-phys Res Commun. 2009 Jul 3;384(3):366-71.
82. Adenuga D, Yao H, March TH, Seagrave J, Rahman I. His-tone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol. 2009 Apr;40(4):464-73.
83. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinfammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Apr 15;177(8):861-70.
84. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A. Inhibition of PI3Kdelta restores glucocorti-coid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med. 2009 Apr 1;179(7):542-8.
85. Adenuga D, Rahman I. Protein kinase CK2-mediated phosphorylation of HDAC2 regulates co-repressor formation, deacetylase activity and acetylation of HDAC2 by cigarette smoke and aldehydes. Arch Biochem Biophys. 2010 Jun 1;498(1):62-73.
86. Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 2006 Jul;116(7):1853-64.
87. Bolger TA, Yao TP. Intracellular traffcking of histone deacetylase 4 regulates neuronal cell death. J Neurosci. 2005 Oct 12;25(41):9544-53.
88. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004 Oct;24(19):8374-85.
89. Chang S, Bezprozvannaya S, Li S, Olson EN. An expression screen reveals modulators of class II histone deacety-lase phosphorylation. Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8120-5.
90. Parra M, Kasler H, McKinsey TA, Olson EN, Verdin E. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem. 2005 Apr 8;280(14):13762-70.
91. Dequiedt F, Van LJ, Lecomte E, Van D, V, Seufferlein T, Vandenheede JR, Wattiez R, Kettmann R. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J Exp Med. 2005 Mar 7;201(5):793-804.
92. Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem. 2010 Jun;45(6):2095-116.
93. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008 Jan 15;409(2):581-9.
94. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubu-lin deacetylation. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4389-94.
95. Bieliauskas AV, Pfum MK. Isoform-selective his-tone deacetylase inhibitors. Chem Soc Rev. 2008 Jul;37(7):1402-13.
96. Ellis L, Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel). 2010 Aug 1;3(8):2411-69.
97. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009 Jun 15;15(12):3958-69.
98. Schemies J, Sippl W, Jung M. Histone deacetylase inhibitors that target tubulin. Cancer Lett. 2009 Aug 8;280(2):222-32.
99. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufer P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxam-ic acid exhibits antiinfammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2995-3000.
100. Carta S, Tassi S, Semino C, Fossati G, Mascagni P, Din-arello CA, Rubartelli A. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood. 2006 Sep 1;108(5):1618-26.
101. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA, Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of pro-infammatory cytokines in vitro and systemic infamma-tion in vivo. Mol Med. 2005 Jan;11(1-12):1-15.
102. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, tricho-statin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 2003 May 1;101(9):3451-9.
103. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume DA, Irvine KM, Matthias P, Fairlie DP, Sweet MJ. Differential effects of selective HDAC inhibitors on macrophage infamma-tory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol. 2010 Jun;87(6):1103-14.
104. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Mi-connet I, Schrenzel J, Francois P, Calandra T. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood. 2011 Jan 27;117(4):1205-17.
105. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2007 Feb 1;109(3):1123-30.
106. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacety-lase inhibitor LAQ824 augments infammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol. 2011 Apr 1;186(7):3986-96.
107. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Mau-rin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinil-la-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009 Jan;10(1):92-100.
108. Nencioni A, Beck J, Werth D, Grunebach F, Patrone F, Ballestrero A, Brossart P. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res. 2007 Jul 1;13(13):3933-41.
109. Wang B, Morinobu A, Horiuchi M, Liu J, Kumagai S. Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. Cell Immunol. 2008 May;253(1-2):54-8.
110. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, Dalpke AH. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinfam-matory gene expression by impairing transcription factor recruitment. Immunology. 2007 Dec;122(4):596-606.
111. Bosisio D, Vulcano M, Del Prete A, Sironi M, Salvi V, Sa-logni L, Riboldi E, Leoni F, Dinarello CA, Girolomoni G, Sozzani S. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol. 2008 Dec;84(6):1540-8.
112. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA, Ferrara JL. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest. 2008 Jul;118(7):2562-73.
113. Salvi V, Bosisio D, Mitola S, Andreoli L, Tincani A, Soz-zani S. Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology. 2010 Sep;215(9-10):756-61.
114. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Oga-wa K, Hotokebuchi T, Kohashi O, Kukita A. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol. 2005 Nov 1;175(9):5809-16.
115. Yi T, Baek JH, Kim HJ, Choi MH, Seo SB, Ryoo HM, Kim GS, Woo KM. Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp Mol Med. 2007 Apr 30;39(2):213-21.
116. Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Mi-chelsen BK, Odum N. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood. 2003 Feb 15;101(4):1430-8.
117. Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL, Hancock WW. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol. 2010 Sep;136(3):348-63.
118. Samanta A, Li B, Song X, Bembas K, Zhang G, Katsumata M, Saouaf SJ, Wang Q, Hancock WW, Shen Y, Greene MI. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14023-7.
119. Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, Saouaf SJ, Greene MI. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4571-6.
120. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, Brenkman AB, Hijnen DJ, Mutis T, Kalkhoven E, Prakken BJ, Coffer PJ. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood. 2010 Feb 4;115(5):965-74.
121. Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G, Hancock WW. Sirtuin-1 targeting promotes foxp3+ T-regula-tory cell function and prolongs allograft survival. Mol Cell Biol. 2011 Mar;31(5):1022-9.
122. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, Distler JH, Gay RE, Kolling C, Moch H, Michel BA, Gay S, Distler O, Jungel A. Histone deacety-lase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 2007 Apr;56(4):1087-93.
123. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacety-lases in rheumatoid arthritis synovial fbroblasts. J Rheu-matol. 2009 Aug;36(8):1580-9.
124. Maciejewska-Rodrigues H, Karouzakis E, Strietholt S, Hemmatazad H, Neidhart M, Ospelt C, Gay RE, Michel BA, Pap T, Gay S, Jungel A. Epigenetics and rheumatoid arthritis: the role of SENP1 in the regulation of MMP-1 expression. J Autoimmun. 2010 Aug;35(1):15-22.
125. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in infammatory and autoimmune diseases. Arthritis Rheum. 2009 May;60(5):1210-21.
126. Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furu-matsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ni-nomiya Y, Inoue H, Asahara H. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004 Oct;50(10):3365-76.
127. Jungel A, Baresova V, Ospelt C, Simmen BR, Michel BA, Gay RE, Gay S, Seemayer CA, Neidhart M. Trichosta-tin A sensitises rheumatoid arthritis synovial fbroblasts for TRAIL-induced apoptosis. Ann Rheum Dis. 2006 Jul;65(7):910-2.
128. Morinobu A, Wang B, Liu J, Yoshiya S, Kurosaka M, Kumagai S. Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fbroblasts. J Rheumatol. 2006 Jun;33(6):1052-60.
129. Choo QY, Ho PC, Tanaka Y, Lin HS. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fbroblastic E11 cells. Rheumatology (Oxford). 2010 Aug;49(8):1447-60.
130. Shimazu T, Komatsu Y, Nakayama KI, Fukazawa H, Horinouchi S, Yoshida M. Regulation of SV40 large T- antigen stability by reversible acetylation. Oncogene. 2006 Nov 30;25(56):7391-400.
131. Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwards DR, Cawston TE, Clark IM. Histone deacety-lase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther. 2005;7(3):R503-512.
132. Chabane N, Zayed N, Aff H, Mfuna-Endam L, Bender-dour M, Boileau C, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H. Histone deacetylase inhibitors suppress in-terleukin-1beta-induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthritis Cartilage. 2008 Oct;16(10):1267-74.
133. Zayed N, El Mansouri FE, Chabane N, Kapoor M, Martel-Pelletier J, Benderdour M, Pelletier JP, Duval N, Fahmi H. Valproic acid suppresses interleukin-1ss-induced microsomal prostaglan-din E2 synthase-1 expression in chondrocytes through upregula-tion of NAB1. J Rheumatol. 2011 Mar;38(3):492-502.
134. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther. 2003 Nov;8(5):707-17.
135. Joosten LA, Leoni F, Meghji S, Mascagni P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol Med. 2011 May;17(5-6):391-6.
136. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepesch-eux L, Bastianelli E, Baron R, Rawadi G, Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007 Apr;150(7):862-72.
137. Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW, Greene MI. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol. 2009 Oct;87(2):99-104.
138. Grabiec AM, Reedquist KA. Histone deacetylases in RA: epigenetics and epiphenomena. Arthritis Res Ther. 2010;12(5):142.
139. Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S, Iagaru N, Stefan M, Dinarello CA. Safety and ef-fcacy of an oral histone deacetylase inhibitor in systemic onset juvenile idiopathic arthritis. Arthritis Rheum. 2011 May;63(5):1452-8.
140. Vojinovic J, Damjanov N. HDAC Inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med. 2011 May;17(5-6):397-403.
141. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000 Sep;47(3):397-403.
142. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, Mascagni P, Fantuzzi G, Dinarello CA, Siegmund B. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol. 2006 Apr 15;176(8):5015-22.
143. Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M, Siegmund B. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 2008 May;57(5):613-22.
144. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2010 Feb;138(2):583-94.
145. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bar-tram P, Christl S, Richter F, Dusel G, Kasper H. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992 Jul;103(1):51-6.
146. Luhrs H, Gerke T, Muller JG, Melcher R, Schauber J, Box-berge F, Scheppach W, Menzel T. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002 Apr;37(4):458-66.
147. Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol. 2006 Jun 15;176(12):7143-7.
148. Hu N, Qiu X, Luo Y, Yuan J, Li Y, Lei W, Zhang G, Zhou Y, Su Y, Lu Q. Abnormal histone modifcation patterns in lupus CD4+ T cells. J Rheumatol. 2008 May;35(5):804-10.
149. Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin A reverses skewed expression of CD154, in-terleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2628-33.
150. Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, Marks PA, Gilkeson GS. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol. 2004 Sep 15;173(6):4171-8.
151. Hu N, Long H, Zhao M, Yin H, Lu Q. Aberrant expression pattern of histone acetylation modifers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice. Scand J Rheu-matol. 2009 Nov;38(6):464-71.
152. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest. 2003 Feb;111(4):539-52.
153. Reilly CM, Thomas M, Gogal R Jr, Olgun S, Santo A, So-dhi R, Samy ET, Peng SL, Gilkeson GS, Mishra N. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun. 2008 Sep;31(2):123-30.
154. Dasgupta S, Zhou Y, Jana M, Banik NL, Pahan K. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol. 2003 Apr 1;170(7):3874-82.
155. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005 Jul;164(1-2):10-21.
156. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Din-arello CA, Ferrara JL. Histone deacetylase inhibitor sub-eroylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3921-6.
157. Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, Mapara MY. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of infam-matory cytokine milieu and involves inhibition of STAT1. Exp Hematol. 2006 Jun;34(6):776-87.
158. Choi S, Reddy P. HDAC inhibition and graft-versus-host disease. Mol Med. 2011 May;17(5-6):404-16.
159. Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock IM. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med. 2004 Jul 15;170(2):141-7.
160. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005 May 12;352(19):1967-76.
161. Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock IM. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med. 2004 Jul 15;170(2):141-7.
162. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005 May 12;352(19):1967-76.
163. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1be-ta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000 Sep;20(18):6891-903.
164. Ito K, Yamamura S, Essilfe-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM. Histone deacetylase 2-mediated deacetyla-tion of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006 Jan 23;203(1):7-13.
165. Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009 May;64(5):424-9.
166. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010 Jun;137(6):1338-44.
167. Marwick JA, Wallis G, Meja K, Kuster B, Bouwmeester T, Chakravarty P, Fletcher D, Whittaker PA, Barnes PJ, Ito K, Adcock IM, Kirkham PA. Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
168. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliott WM, Hogg JC, Adcock IM, Barnes PJ. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Oct 1;182(7):897-904.
169. Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 2007 Mar;7(3):191-201.
170. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, Elliot M, Hogg J, Kharitonov S, Goto H, Bemis JE, Elliott P, Barnes PJ, Ito K. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 2009 Sep;23(9):2810-9.
171. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy. 2005 Jan;35(1):89-96.
172. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 2009 Feb;60(2):317-20.
173. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dumpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neu-bauer G, Ramsden NG, Drewes G. Chemoproteom-ics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011 Mar;29(3):255-65.
174. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fe-dorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang YC, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
175. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dew-ell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prin-jha RK, Lee K, Tarakhovsky A. Suppression of inflammation by a synthetic histone mimic. Nature. 2010 Dec 23;468(7327):1119-23.
176. Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol. 2009;257(1-2):97-104.
177. Manabe H, Nasu Y, Komiyama T, Furumatsu T, Kitamura A, Miyazawa S, Ninomiya Y, Ozaki T, Asahara H, Nishida K. Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fbroblasts. Infamm Res. 2008 Jan;57(1):4-10.
178. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N, Yoshida A, Hirohata S, Ohtsuka A, Ozaki T. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage. 2008 Jun;16(6):723-32.